We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+7.6%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$696M
AUM Growth
+$65M
Cap. Flow
+$38.4M
Cap. Flow %
5.52%
Top 10 Hldgs %
28.66%
Holding
112
New
8
Increased
33
Reduced
36
Closed
4

Top Buys

Rank Stock Value
1
NVCR icon
NovoCure
NVCR
+$15.7M
2
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$12M
3
EXEL icon
Exelixis
EXEL
+$8.89M
4
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$8.34M
5
SNY icon
Sanofi
SNY
+$7.65M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$10.6M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$9.58M
3
SUPN icon
Supernus Pharmaceuticals
SUPN
+$7.12M
4
ESPR
Esperion Therapeutics
ESPR
+$6.62M
5
BIIB icon
Biogen
BIIB
+$5.16M

Sector Composition

Rank Sector Weight
1 Healthcare 92.59%
2 Financials 0.93%
3 Technology 0.13%
4 Energy 0.1%
5 Consumer Discretionary 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABBV icon
26
AbbVie
ABBV
$433B
$9.79M 1.41%
135,000
+5,000
+4% +$336K
MRK icon
27
Merck
MRK
$316B
$8.97M 1.29%
146,720
-20,960
-13% -$1.28M
HUM icon
28
Humana
HUM
$45B
$8.42M 1.21%
35,000
+3,000
+9% +$679K
HCA icon
29
HCA Healthcare
HCA
$88B
$8.26M 1.19%
94,707
-10,000
-10% -$846K
CNC icon
30
Centene
CNC
$31.5B
$7.99M 1.15%
200,000
+24,814
+14% +$937K
ALKS icon
31
Alkermes
ALKS
$8.33B
$7.85M 1.13%
135,409
-5,000
-4% -$290K
WBA
32
DELISTED
Walgreens Boots Alliance
WBA
$7.83M 1.12%
100,000
+55,000
+122% +$4.53M
SNY icon
33
Sanofi
SNY
$102B
$7.67M 1.1%
+160,000
New +$7.65M
ELGX
34
DELISTED
Endologix Inc
ELGX
$7.66M 1.1%
157,500
-2,500
-2% -$147K
DXCM icon
35
DexCom
DXCM
$32.9B
$7.63M 1.1%
417,520
+189,920
+83% +$3.51M
CI icon
36
Cigna
CI
$74.5B
$7.53M 1.08%
45,000
-19,000
-30% -$3.05M
REGN icon
37
Regeneron Pharmaceuticals
REGN
$78.2B
$7.42M 1.06%
15,100
-21,900
-59% -$9.58M
CVS icon
38
CVS Health
CVS
$133B
$6.84M 0.98%
85,000
-45,000
-35% -$3.55M
ADMS
39
DELISTED
Adamas Pharmaceuticals
ADMS
$6.44M 0.92%
368,166
+213,166
+138% +$3.53M
ALNY icon
40
Alnylam Pharmaceuticals
ALNY
$29.5B
$6.4M 0.92%
80,190
-49,810
-38% -$3.18M
BMY icon
41
Bristol-Myers Squibb
BMY
$135B
$6.33M 0.91%
113,595
-87,405
-43% -$4.76M
LIVN icon
42
LivaNova
LIVN
$4.69B
$6.23M 0.9%
+101,854
New +$5.76M
PTLA
43
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$6.22M 0.89%
110,805
-10,000
-8% -$401K
KITE
44
DELISTED
Kite Pharma, Inc.
KITE
$6.22M 0.89%
60,000
-50,000
-45% -$4.08M
UHS icon
45
Universal Health Services
UHS
$10.2B
$6.1M 0.88%
50,000
+15,000
+43% +$1.79M
AMGN icon
46
Amgen
AMGN
$204B
$6.03M 0.87%
35,000
-65,000
-65% -$10.6M
RVNC
47
DELISTED
Revance Therapeutics, Inc.
RVNC
$5.81M 0.83%
220,000
+10,000
+5% +$223K
DVAX
48
DELISTED
Dynavax Technologies
DVAX
$5.67M 0.81%
587,330
-397,366
-40% -$2.58M
AET
49
DELISTED
Aetna Inc
AET
$5.62M 0.81%
37,000
-15,000
-29% -$2.12M
NBIX icon
50
Neurocrine Biosciences
NBIX
$16.9B
$5.52M 0.79%
120,000
+35,000
+41% +$1.7M
1
2
3 4 5

Similar funds

BBI
Baxter Bros Inc Riverside, Connecticut $810M AUM 16.24% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
DWA
Dorsey Wright & Associates Pasadena, California $807M AUM 65.46% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return

Rhenman & Partners Asset Management's Q2 2017 Portfolio in Review

As of Q2 2017, Rhenman & Partners Asset Management held 112 positions worth $696M, up 10% from $631M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rhenman & Partners Asset Management deployed $38.4M of net new capital in Q2 2017, opening 8 new positions and adding to 33 existing holdings. Its largest new stake was NovoCure: 1,216,314 shares worth $21M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 92% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Amgen, an estimated $10.6M trimmed.

  • Rhenman & Partners Asset Management's largest Q2 2017 buy was NovoCure: 1,216,314 shares worth $21M.
  • Rhenman & Partners Asset Management added most to Exelixis in Q2 2017, an estimated $8.89M increase.
  • Rhenman & Partners Asset Management's biggest Q2 2017 reduction was Amgen, cutting an estimated $10.6M.
  • Rhenman & Partners Asset Management fully exited Viatris in Q2 2017, selling an estimated $3.51M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 29% of its $696M portfolio in Q2 2017.
  • Rhenman & Partners Asset Management opened 8 new positions and closed 4 in Q2 2017.
  • Rhenman & Partners Asset Management's portfolio value rose 10% quarter-over-quarter to $696M.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2017, filed 11 Jul 2017.